Last updated: February 20, 2026
Diatrizoate meglumine is a radiopaque contrast agent used in diagnostic imaging. Its global production involves several key pharmaceutical substrates and intermediates supplied by multiple manufacturers.
Major Suppliers Overview
Broadly, suppliers fall into two categories:
- Raw material producers for diatrizoate salts
- Finished formulation providers
Most bulk raw material is produced by specialty chemical manufacturers, whereas finished products are supplied by pharmaceutical companies with regulatory approval.
Raw Material Suppliers
Major chemical producers supply diatrizoate meglumine's raw material components, including diatrizoic acid and meglumine. These are often produced in countries with established chemical manufacturing sectors.
| Supplier |
Country |
Product |
Capacity |
Notes |
| Sigma-Aldrich (MilliporeSigma) |
USA |
Diatrizoic acid |
High |
Global distributor of chemicals and pharmaceuticals |
| Merck KGaA |
Germany |
Meglumine (N-methylglucamine) |
High |
Supplies pharmaceutical excipients |
| Thermo Fisher Scientific |
USA |
Diatrizoic acid |
Moderate |
Distributes chemicals for research & pharma |
| Shanghai Biokangtai Co., Ltd. |
China |
Diatrizoic acid |
Moderate |
Expanding in Asia, competitive pricing |
| Jiangsu Hengrui Medicine Co., Ltd. |
China |
Meglumine |
Limited |
Focused on finished injectable formulations |
Finished Formulation Suppliers
Finished pharmaceutical products containing diatrizoate meglumine are supplied by licensed manufacturers. These companies obtain raw materials from the above suppliers and ensure compliance with regulatory standards such as FDA (USA), EMA (Europe), and PMDA (Japan).
| Manufacturer |
Country |
Market Focus |
Regulatory Status |
Notes |
| GE Healthcare (now part of Danaher) |
USA |
Diagnostic imaging agents |
Approved in US & EU |
One of the largest global suppliers |
| Bracco Diagnostics Inc. |
Italy |
Radiopaque contrast agents |
Approved worldwide |
Deep presence in Europe and Americas |
| Guerbet Group |
France |
Radiology contrast media |
Globally licensed |
Focus on Europe, emerging markets |
| BTG International Ltd. |
UK |
Specialty pharma products |
Approved in multiple regions |
Offers limited formulations |
| Hoffmann-La Roche (Roche Diagnostics) |
Switzerland |
Diagnostic products |
Global |
Supplies via regional licensing agreements |
Regulatory Considerations
Manufacturers must comply with Good Manufacturing Practice (GMP) standards to produce diatrizoate meglumine. Regulatory approval depends on region:
- US: FDA approval required
- EU: EMA authorization
- Japan: PMDA clearance
Supply chains are often segmented by licensing agreements, impacting availability in different markets.
Supply Chain Dynamics
- Raw material producers in China and India have increased capacity, reducing costs but raising concerns over quality control for certain suppliers.
- Established companies maintain high-quality standards with rigorous audits.
- Lead times for raw materials may range between 2-4 weeks depending on regional logistics.
- Finished product suppliers depend on raw material availability and regulatory approvals, influencing global supply stability during public health crises.
Key Takeaways
- Diatrizoate meglumine raw materials are sourced from chemical suppliers mainly in the US, Europe, and China.
- Leading finished suppliers include GE Healthcare, Bracco, and Guerbet.
- Supply chain complexity is influenced by regulatory approvals, regional manufacturing standards, and geopolitical factors.
- Market presence varies by geography; North American and European markets rely heavily on established global players.
- Cost, quality, and regulatory compliance shape supplier selection.
FAQs
1. Who are the primary global suppliers of diatrizoate meglumine?
GE Healthcare, Bracco Diagnostics, and Guerbet Group are the main providers of finished formulations. Raw materials originate from chemical suppliers like Sigma-Aldrich and Merck KGaA.
2. Are there regional differences in sourcing diatrizoate meglumine?
Yes. North America and Europe rely on established suppliers with strict regulatory standards, while China and India supply raw materials at lower costs, often with variable quality standards.
3. What factors influence supplier choice for pharmaceutical manufacturers?
Regulatory compliance, raw material quality, cost, and supply chain reliability are key factors.
4. Is there a risk of supply disruption?
Yes. Supply chains are vulnerable to geopolitical issues, regional manufacturing capacity changes, and pandemic-related logistics disruptions.
5. How do regulatory approvals impact global supply?
Regulatory approvals determine whether finished products or raw materials can be legally marketed in a specific region, affecting supply availability and market access.
References
[1] Food and Drug Administration. (2022). Regulations and Guidance for Contrast Media. https://www.fda.gov
[2] European Medicines Agency. (2022). Guideline on the specifications for radiopaque contrast media. https://www.ema.europa.eu
[3] Pharmacopoeia Standards. (2020). United States Pharmacopeia and European Pharmacopoeia standards for diatrizoic acid and meglumine.
